;PMID: 10385652
;source_file_868.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..33] = [t:0..33]
;1)sentence:[e:39..174] = [t:39..174]
;2)section:[e:178..261] = [t:178..261]
;3)section:[e:265..349] = [t:265..349]
;4)sentence:[e:353..609] = [t:353..609]
;5)sentence:[e:610..736] = [t:610..736]
;6)sentence:[e:737..917] = [t:737..917]
;7)sentence:[e:918..1007] = [t:918..1007]
;8)sentence:[e:1008..1175] = [t:1008..1175]
;9)sentence:[e:1176..1282] = [t:1176..1282]
;10)sentence:[e:1284..1455] = [t:1284..1455]
;11)sentence:[e:1456..1643] = [t:1456..1643]
;12)sentence:[e:1644..1919] = [t:1644..1919]
;13)sentence:[e:1920..2074] = [t:1920..2074]
;14)section:[e:2078..2123] = [t:2078..2123]
;Token/POS Errors
;ERROR_Token in entity file but not tree[1140..1142] 2.
;ERROR_Token in entity file but not tree[1143..1144] 5
;ERROR_Token in tree file but not entity[1140..1144] 2. 5

;section 0 Span:0..33
;Hepatology. 1999 Jul;30(1):160-8.
(SEC
  (FRAG (NN:[0..10] Hepatology) (IN:[10..11] .) (CD:[12..16] 1999)
        (CD:[17..24] Jul;30-LRB-) (CD:[24..25] 1) (-RRB-:[25..26] -RRB-)
        (CD:[26..30] :160) (HYPH:[30..31] -) (CD:[31..33] 8.)))

;sentence 1 Span:39..174
;Carbon monoxide-mediated alterations in paracellular permeability and
;vesicular  transport in acetaminophen-treated perfused rat liver.
;[39..54]:substance:"Carbon monoxide"
;[133..146]:substance:"acetaminophen"
(SENT
  (NP-HLN
    (NP
      (ADJP
        (NML (NN:[39..45] Carbon) (NN:[46..54] monoxide))
        (HYPH:[54..55] -) (VBN:[55..63] mediated))
      (NNS:[64..75] alterations))
    (PP (IN:[76..78] in)
      (NP
        (NP (JJ:[79..91] paracellular) (NN:[92..104] permeability))
        (CC:[105..108] and)
        (NP (JJ:[109..118] vesicular) (NN:[120..129] transport))))
    (PP-LOC (IN:[130..132] in)
      (NP
        (ADJP (NN:[133..146] acetaminophen) (HYPH:[146..147] -)
              (VBN:[147..154] treated))
        (VBN:[155..163] perfused) (NN:[164..167] rat) (NN:[168..173] liver)))
    (.:[173..174] .)))

;section 2 Span:178..261
;Mori M, Suematsu M, Kyokane T, Sano T, Suzuki H, Yamaguchi T, Ishimura Y,
;Ishii  H.
(SEC
  (FRAG (NNP:[178..182] Mori) (NNP:[183..185] M,) (NNP:[186..194] Suematsu)
        (VBD:[195..197] M,) (NNP:[198..205] Kyokane) (NNP:[206..207] T)
        (VBD:[207..208] ,) (NNP:[209..213] Sano) (NNP:[214..215] T)
        (,:[215..216] ,) (NNP:[217..223] Suzuki) (NNP:[224..225] H)
        (VBD:[225..226] ,) (NNP:[227..236] Yamaguchi) (NNP:[237..238] T)
        (,:[238..239] ,) (NNP:[240..248] Ishimura) (NNP:[249..250] Y)
        (,:[250..251] ,) (NNP:[252..257] Ishii) (NNP:[259..261] H.)))

;section 3 Span:265..349
;Department of Internal Medicine, School of Medicine, Keio University, Tokyo, 
;Japan.
(SEC
  (FRAG (NNP:[265..275] Department) (IN:[276..278] of) (NNP:[279..287] Internal)
        (NNP:[288..296] Medicine) (NNP:[296..297] ,) (NNP:[298..304] School)
        (IN:[305..307] of) (NNP:[308..316] Medicine) (,:[316..317] ,)
        (NNP:[318..322] Keio) (NNP:[323..333] University) (,:[333..334] ,)
        (NNP:[335..340] Tokyo) (,:[340..341] ,) (NNP:[343..348] Japan)
        (.:[348..349] .)))

;sentence 4 Span:353..609
;This study aimed to examine whether acetaminophen (AAP), an anti-inflammatory
; agent producing hepatocellular damages with its overdose, evokes
;hepatocellular  dysfunction through mechanisms involving carbon monoxide (CO)
;generated by heme  oxygenase (HO).
;[389..402]:substance:"acetaminophen"
;[404..407]:substance:"AAP"
;[413..437]:substance:"anti-inflammatory  agent"
;[554..569]:substance:"carbon monoxide"
;[571..573]:substance:"CO"
;[588..603]:substance:"heme  oxygenase"
;[605..607]:substance:"HO"
(SENT
  (S
    (NP-SBJ (DT:[353..357] This) (NN:[358..363] study))
    (VP (VBD:[364..369] aimed)
      (S
        (NP-SBJ (-NONE-:[369..369] *))
        (VP (TO:[370..372] to)
          (VP (VB:[373..380] examine)
            (SBAR (IN:[381..388] whether)
              (S
                (NP-SBJ
                  (NP
                    (NP (NN:[389..402] acetaminophen))
                    (NP (-LRB-:[403..404] -LRB-) (NN:[404..407] AAP)
                        (-RRB-:[407..408] -RRB-)))
                  (,:[408..409] ,)
                  (NP
                    (NP (DT:[410..412] an)
                      
                      (ADJP (AFX:[413..417] anti) (HYPH:[417..418] -)
                            (JJ:[418..430] inflammatory))
                      (NN:[432..437] agent))
                    (VP (VBG:[438..447] producing)
                      (NP (JJ:[448..462] hepatocellular)
                          (NNS:[463..470] damages))
                      (PP (IN:[471..475] with)
                        (NP (PRP$:[476..479] its) (NN:[480..488] overdose))))))
                (,:[488..489] ,)
                (VP (VBZ:[490..496] evokes)
                  (NP (JJ:[497..511] hepatocellular) (NN:[513..524] dysfunction))
                  (PP (IN:[525..532] through)
                    (NP
                      (NP (NNS:[533..543] mechanisms))
                      (VP (VBG:[544..553] involving)
                        (NP
                          (NP
                            (NP (NN:[554..560] carbon) (NN:[561..569] monoxide))
                            (NP (-LRB-:[570..571] -LRB-) (NN:[571..573] CO)
                                (-RRB-:[573..574] -RRB-)))
                          (VP (VBN:[575..584] generated)
                            (NP (-NONE-:[584..584] *))
                            (PP (IN:[585..587] by)
                              (NP-LGS
                                (NP (NN:[588..592] heme)
                                    (NN:[594..603] oxygenase))
                                (NP (-LRB-:[604..605] -LRB-) (NN:[605..607] HO)
                                    (-RRB-:[607..608] -RRB-))))))))))))))))
    (.:[608..609] .)))

;sentence 5 Span:610..736
;In perfused rat livers, CO and bilirubin were determined in  venous perfusate
;and bile samples as indices of heme degradation.
;[634..636]:substance:"CO"
;[641..650]:substance:"bilirubin"
;[678..687]:substance:"perfusate"
;[692..696]:substance:"bile"
;[719..723]:substance:"heme"
(SENT
  (S
    (PP (IN:[610..612] In)
      (NP (VBN:[613..621] perfused) (NN:[622..625] rat) (NNS:[626..632] livers)))
    (,:[632..633] ,)
    (NP-SBJ-2 (NN:[634..636] CO) (CC:[637..640] and) (NN:[641..650] bilirubin))
    (VP (VBD:[651..655] were)
      (VP (VBN:[656..666] determined)
        (NP-2 (-NONE-:[666..666] *))
        (PP-LOC (IN:[667..669] in)
          (NP
            (NP (JJ:[671..677] venous) (NN:[678..687] perfusate)
              (NML-1 (-NONE-:[687..687] *P*)))
            (CC:[688..691] and)
            (NP (NN:[692..696] bile)
              (NML-1 (NNS:[697..704] samples)))))
        (PP (IN:[705..707] as)
          (NP
            (NP (NNS:[708..715] indices))
            (PP (IN:[716..718] of)
              (NP (NN:[719..723] heme) (NN:[724..735] degradation)))))))
    (.:[735..736] .)))

;sentence 6 Span:737..917
;Biliary  excretion of transportally injected horseradish peroxidase was also
;determined  to assess paracellular junctional permeability and vesicular
;transport across  hepatocytes.
;[782..804]:substance:"horseradish peroxidase"
(SENT
  (S
    (NP-SBJ-1
      (NP (JJ:[737..744] Biliary) (NN:[746..755] excretion))
      (PP (IN:[756..758] of)
        (NP
          (ADJP (RB:[759..772] transportally) (VBN:[773..781] injected))
           (NN:[782..793] horseradish) (NN:[794..804] peroxidase))))
    (VP (VBD:[805..808] was) (RB:[809..813] also)
      (VP (VBN:[814..824] determined)
        (NP-1 (-NONE-:[824..824] *))
        (S-PRP
          (NP-SBJ (-NONE-:[824..824] *))
          (VP (TO:[826..828] to)
            (VP (VB:[829..835] assess)
              (NP
                (NP (JJ:[836..848] paracellular) (JJ:[849..859] junctional)
                    (NN:[860..872] permeability))
                (CC:[873..876] and)
                (NP (JJ:[877..886] vesicular) (NN:[887..896] transport)))
              (PP (IN:[897..903] across)
                (NP (NNS:[905..916] hepatocytes))))))))
    (.:[916..917] .)))

;sentence 7 Span:918..1007
;AAP at 20 mmol/L induced a transient choleresis, followed by a  reduction of
;bile output.
;[918..921]:substance:"AAP"
;[925..927]:quantitative-value:"20"
;[928..934]:quantitative-units:"mmol/L"
;[995..999]:substance:"bile"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[918..921] AAP))
      (PP (IN:[922..924] at)
        (NP
          (NP (CD:[925..927] 20) (NN:[928..932] mmol))
          (PP (SYM:[932..933] /)
            (NP (NN:[933..934] L))))))
    (VP (VBD:[935..942] induced)
      (NP
        (NP (DT:[943..944] a) (JJ:[945..954] transient)
            (NN:[955..965] choleresis))
        (,:[965..966] ,)
        (VP (VBN:[967..975] followed)
          (NP (-NONE-:[975..975] *))
          (PP (IN:[976..978] by)
            (NP-LGS
              (NP (DT:[979..980] a) (NN:[982..991] reduction))
              (PP (IN:[992..994] of)
                (NP (NN:[995..999] bile) (NN:[1000..1006] output))))))))
    (.:[1006..1007] .)))

;sentence 8 Span:1008..1175
;Under these circumstances, the release of CO and  bilirubin IXalpha, terminal
;products of the HO-mediated heme degradation, became  2. 5-fold greater than
;the control.
;[1050..1052]:substance:"CO"
;[1058..1075]:substance:"bilirubin IXalpha"
;[1086..1094]:substance:"products"
;[1102..1104]:substance:"HO"
;[1114..1118]:substance:"heme"
;[1140..1149]:quantitative-value:"2. 5-fold"
(SENT
  (S
    (PP (IN:[1008..1013] Under)
      (NP (DT:[1014..1019] these) (NNS:[1020..1033] circumstances)))
    (,:[1033..1034] ,)
    (NP-SBJ
      (NP (DT:[1035..1038] the) (NN:[1039..1046] release))
      (PP (IN:[1047..1049] of)
        (NP
          (NP
            (NP (NN:[1050..1052] CO))
            (CC:[1053..1056] and)
            (NP (NN:[1058..1067] bilirubin) (NN:[1068..1075] IXalpha)))
          (,:[1075..1076] ,)
          (NP
            (NP (JJ:[1077..1085] terminal) (NNS:[1086..1094] products))
            (PP (IN:[1095..1097] of)
              (NP (DT:[1098..1101] the)
                (ADJP (NN:[1102..1104] HO) (HYPH:[1104..1105] -)
                      (VBN:[1105..1113] mediated))
                (NN:[1114..1118] heme) (NN:[1119..1130] degradation)))))))
    (,:[1130..1131] ,)
    (VP (VBD:[1132..1138] became)
      (ADJP-PRD
        (ADJP
          (ADVP (CD:[1140..1144] 2.-SP-5) (HYPH:[1144..1145] -)
                (RB:[1145..1149] fold))
          (JJR:[1150..1157] greater))
        (PP (IN:[1158..1162] than)
          (NP (DT:[1163..1166] the) (NN:[1167..1174] control)))))
    (.:[1174..1175] .)))

;sentence 9 Span:1176..1282
;The rate of CO production appeared  stoichiometric to the degradation rate of
;microsomal cytochrome P-450.
;[1188..1190]:substance:"CO"
;[1265..1281]:cyp450:"cytochrome P-450"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1176..1179] The) (NN:[1180..1184] rate))
      (PP (IN:[1185..1187] of)
        (NP (NN:[1188..1190] CO) (NN:[1191..1201] production))))
    (VP (VBD:[1202..1210] appeared)
      (ADJP-PRD (JJ:[1212..1226] stoichiometric)
        (PP (TO:[1227..1229] to)
          (NP
            (NP (DT:[1230..1233] the) (NN:[1234..1245] degradation)
                (NN:[1246..1250] rate))
            (PP (IN:[1251..1253] of)
              (NP (JJ:[1254..1264] microsomal)
                 (NN:[1265..1275] cytochrome) (NN:[1276..1281] P-450)))))))
    (.:[1281..1282] .)))

;sentence 10 Span:1284..1455
;Mechanisms for the AAP-induced cholestasis involved an increase in the 
;junctional permeability that coincided with a reduction of vesicular
;transport  across hepatocytes.
;[1303..1306]:substance:"AAP"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[1284..1294] Mechanisms))
      (PP (IN:[1295..1298] for)
        (NP (DT:[1299..1302] the)
          (ADJP (NN:[1303..1306] AAP) (HYPH:[1306..1307] -)
                (VBN:[1307..1314] induced))
          (NN:[1315..1326] cholestasis))))
    (VP (VBD:[1327..1335] involved)
      (NP
        (NP
          (NP (DT:[1336..1338] an) (NN:[1339..1347] increase))
          (PP (IN:[1348..1350] in)
            (NP (DT:[1351..1354] the) (JJ:[1356..1366] junctional)
                (NN:[1367..1379] permeability))))
        (SBAR
          (WHNP-1 (WDT:[1380..1384] that))
          (S
            (NP-SBJ-1 (-NONE-:[1384..1384] *T*))
            (VP (VBD:[1385..1394] coincided)
              (PP-CLR (IN:[1395..1399] with)
                (NP
                  (NP (DT:[1400..1401] a) (NN:[1402..1411] reduction))
                  (PP (IN:[1412..1414] of)
                    (NP
                      (NP (JJ:[1415..1424] vesicular)
                          (NN:[1425..1434] transport))
                      (PP (IN:[1436..1442] across)
                        (NP (NNS:[1443..1454] hepatocytes))))))))))))
    (.:[1454..1455] .)))

;sentence 11 Span:1456..1643
;Clotrimazole, a cytochrome P-450 inhibitor, or zinc  protoporphyrin IX, an HO
;inhibitor, but not copper protoporphyrin IX, which did  not inhibit HO,
;attenuated these AAP-induced changes.
;[1456..1468]:substance:"Clotrimazole"
;[1472..1488]:cyp450:"cytochrome P-450"
;[1489..1498]:substance:"inhibitor"
;[1503..1526]:substance:"zinc  protoporphyrin IX"
;[1531..1533]:substance:"HO"
;[1534..1543]:substance:"inhibitor"
;[1553..1577]:substance:"copper protoporphyrin IX"
;[1602..1604]:substance:"HO"
;[1623..1626]:substance:"AAP"
(SENT
  (S
    (NP-SBJ
      (NP
        (NP (NN:[1456..1468] Clotrimazole))
        (,:[1468..1469] ,)
        (NP (DT:[1470..1471] a)
          (NML (NN:[1472..1482] cytochrome) (NN:[1483..1488] P-450))
          (NN:[1489..1498] inhibitor)))
      (,:[1498..1499] ,) (CC:[1500..1502] or)
      (NP
        (NP (NN:[1503..1507] zinc) (NN:[1509..1523] protoporphyrin)
            (CD:[1524..1526] IX))
        (,:[1526..1527] ,)
        (NP (DT:[1528..1530] an) (NN:[1531..1533] HO)
            (NN:[1534..1543] inhibitor)))
      (,:[1543..1544] ,)
      (CONJP (CC:[1545..1548] but) (RB:[1549..1552] not))
      (NP
        (NP (NN:[1553..1559] copper) (NN:[1560..1574] protoporphyrin)
            (CD:[1575..1577] IX))
        (,:[1577..1578] ,)
        (SBAR
          (WHNP-1 (WDT:[1579..1584] which))
          (S
            (NP-SBJ-1 (-NONE-:[1584..1584] *T*))
            (VP (VBD:[1585..1588] did) (RB:[1590..1593] not)
              (VP (VB:[1594..1601] inhibit)
                (NP (NN:[1602..1604] HO))))))))
    (,:[1604..1605] ,)
    (VP (VBD:[1606..1616] attenuated)
      (NP (DT:[1617..1622] these)
        (ADJP (NN:[1623..1626] AAP) (HYPH:[1626..1627] -)
              (VBN:[1627..1634] induced))
        (NNS:[1635..1642] changes)))
    (.:[1642..1643] .)))

;sentence 12 Span:1644..1919
;Furthermore,  administration of CO at concentrations comparable with those
;induced by AAP  elicited a marked elevation of the paracellular junctional
;permeability  concurrent with a reduction of transcellular vesicular
;transport, mimicking  effects of the AAP administration.
;[1676..1678]:substance:"CO"
;[1730..1733]:substance:"AAP"
;[1900..1903]:substance:"AAP"
(SENT
  (S
    (ADVP (RB:[1644..1655] Furthermore))
    (,:[1655..1656] ,)
    (NP-SBJ
      (NP (NN:[1658..1672] administration))
      (PP (IN:[1673..1675] of)
        (NP
          (NP (NN:[1676..1678] CO))
          (PP (IN:[1679..1681] at)
            (NP
              (NP (NNS:[1682..1696] concentrations))
              (ADJP (JJ:[1697..1707] comparable)
                (PP (IN:[1708..1712] with)
                  (NP
                    (NP (DT:[1713..1718] those))
                    (VP (VBN:[1719..1726] induced)
                      (NP (-NONE-:[1726..1726] *))
                      (PP (IN:[1727..1729] by)
                        (NP-LGS (NN:[1730..1733] AAP))))))))))))
    (VP (VBD:[1735..1743] elicited)
      (NP
        (NP (DT:[1744..1745] a) (JJ:[1746..1752] marked)
            (NN:[1753..1762] elevation))
        (PP (IN:[1763..1765] of)
          (NP
            (NP (DT:[1766..1769] the) (JJ:[1770..1782] paracellular)
                (JJ:[1783..1793] junctional) (NN:[1794..1806] permeability))
            (ADJP (JJ:[1808..1818] concurrent)
              (PP (IN:[1819..1823] with)
                (NP
                  (NP (DT:[1824..1825] a) (NN:[1826..1835] reduction))
                  (PP (IN:[1836..1838] of)
                    (NP (JJ:[1839..1852] transcellular)
                        (JJ:[1853..1862] vesicular) (NN:[1863..1872] transport)))))))))
      (,:[1872..1873] ,)
      (S-ADV
        (NP-SBJ (-NONE-:[1873..1873] *))
        (VP (VBG:[1874..1883] mimicking)
          (NP
            (NP (NNS:[1885..1892] effects))
            (PP (IN:[1893..1895] of)
              (NP (DT:[1896..1899] the) (NN:[1900..1903] AAP)
                  (NN:[1904..1918] administration)))))))
    (.:[1918..1919] .)))

;sentence 13 Span:1920..2074
;Thus, CO serves as a putative regulator of  hepatocellular function that is
;overproduced through acute heme degradation  during xenobiotic
;transformation.
;[1926..1928]:substance:"CO"
;[1950..1959]:substance:"regulator"
;[2023..2027]:substance:"heme"
;[2048..2058]:substance:"xenobiotic"
(SENT
  (S
    (ADVP (RB:[1920..1924] Thus))
    (,:[1924..1925] ,)
    (NP-SBJ (NN:[1926..1928] CO))
    (VP (VBZ:[1929..1935] serves)
      (PP-CLR (IN:[1936..1938] as)
        (NP
          (NP
            (NP (DT:[1939..1940] a) (JJ:[1941..1949] putative)
                (NN:[1950..1959] regulator))
            (PP (IN:[1960..1962] of)
              (NP (JJ:[1964..1978] hepatocellular) (NN:[1979..1987] function))))
          (SBAR
            (WHNP-1 (WDT:[1988..1992] that))
            (S
              (NP-SBJ-1 (-NONE-:[1992..1992] *T*))
              (VP (VBZ:[1993..1995] is)
                (VP (VBN:[1996..2008] overproduced)
                  (NP-1 (-NONE-:[2008..2008] *))
                  (PP (IN:[2009..2016] through)
                    (NP (JJ:[2017..2022] acute) (NN:[2023..2027] heme)
                        (NN:[2028..2039] degradation)))
                  (PP-TMP (IN:[2041..2047] during)
                    (NP (JJ:[2048..2058] xenobiotic)
                        (NN:[2059..2073] transformation))))))))))
    (.:[2073..2074] .)))

;section 14 Span:2078..2123
;PMID: 10385652 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2078..2082] PMID) (::[2082..2083] :) (CD:[2084..2092] 10385652)
        (IN:[2093..2094] -LSB-) (NNP:[2094..2100] PubMed) (HYPH:[2101..2102] -)
        (JJ:[2103..2110] indexed) (IN:[2111..2114] for)
        (NNP:[2115..2123] MEDLINE-RSB-)))
